On the Evolution and Contemporary Roles of Bone Remodeling

Osteoporosis: Fourth Edition

Volumn , Issue , 2013, Pages 873-914

  Kostenuik, Paul ^a  

^a AMGEN INC   (United States)

Author keywords

Bisphosphonates; Bone mass and strength; Bone remodeling; Calcium homeostasis; Denosumab; Evolution; Hypocalcemia; Lactation; Menopause; Microcracks; Osteoclasts; Osteomalacia; Pleiotropies; RANKL; Reproduction; Resorption; Tetrapods

Indexed keywords

EID: 84903061791     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-415853-5.00037-6     Document Type: Chapter

References (380)

1. Dobzhansky T. Biology, molecular and organismic. Am Zool 1964, 4:443-452.
2. Seeman E., Delmas P.D. Bone quality: the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354:2250-2261.
3. Seeman E. Bone modeling and remodeling. Crit Rev Eukaryot Gene Expr 2009, 19:219-233.
4. Parfitt A.M. Skeletal heterogeneity and the purposes of bone remodeling. Osteoporosis 1996, 315-329. Academic Press, San Diego, CA. 1st ed. R. Marcus, D. Feldman, J. Kelsey (Eds.).
5. Eaton S.B., Nelson D.A. Calcium in evolutionary perspective. Am J Clin Nutr 1991, 54(Suppl. 1):281S-287S.
6. Prum R.O., Brush A.H. The evolutionary origin and diversification of feathers. Q Rev Biol 2002, 77:261-295.
7. Gould S.J., Lewontin R.C. The spandrels of San Marco and the Panglossian paradigm: a critique of the adaptationist programme. Proc R Soc Lond B Biol Sci 1979, 205:581-598.
8. Witten P.E., Huysseune A. A comparative view on mechanisms and functions of skeletal remodelling in teleost fish, with special emphasis on osteoclasts and their function. Biol Rev 2009, 84:315-346.
9. Witten P.E., Hall B.K. Seasonal changes in the lower jaw skeleton in male Atlantic salmon (Salmo salar L.): remodelling and regression of the kype after spawning. J Anat 2003, 203:435-450.
10. Azuma K., Kobayashi M., Nakamura M., Suzuki N., Yashima S., Iwamuro S., et al. Two osteoclastic markers expressed in multinucleate osteoclasts of goldfish scales. Biochem Biophys Res Commun 2007, 362:594-600.
11. Kawasaki K., Suzuki T., Weiss K.M. Genetic basis for the evolution of vertebrate mineralized tissue. Proc Natl Acad Sci U S A 2004, 101:11356-11361.
12. King G.J., Keeling S.D., Wronski T.J. Histomorphometric study of alveolar bone turnover in orthodontic tooth movement. Bone 1991, 12:401-409.
13. Da Costa Gomez T.M., Barrett J.G., Sample S.J., Radtke C.L., Kalscheur V.L., Lu Y., et al. Up-regulation of site-specific remodeling without accumulation of microcracking and loss of osteocytes. Bone 2005, 37:16-24.
14. Uhthoff H.K., Jaworski Z. Periosteal stress-induced reactions resembling stress fractures. Clin Orthop Rel Res 1985, 199:284-291.
15. Currey J.D. The many adaptations of bone. J Biomech 2003, 36:1487-1495.
16. Parfitt A.M. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 1994, 55:273-286.
17. Teitelbaum S.L. Osteoclasts: what do they do and how do they do it?. Am J Pathol 2007, 170:427-435.
18. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
19. Simonet W.S., Lacey D.L., Dunstan C., Kelley M., Chang M.S., Lüthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
20. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
21. Hsu H., Lacey D.L., Dunstan C., Solovyev I., Colombero A., Timms E., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999, 96:3540-3545.
22. Fleisch H., Fleisch H.A. Bone and mineral metabolism. Bisphosphonates in bone disease: from the laboratory to the patient 1997, 11-31. Parthenon Publishing Group, New York. 3rd ed. H. Fleisch (Ed.).
23. Roschger P., Paschalis E.P., Fratzl P., Klaushofer K. Bone mineralization density distribution in health and disease. Bone 2008, 42:456-466.
24. Frost H.M. Transient-steady state phenomena in microdamage physiology: a proposed algorithm for lamellar bone. Calcif Tissue Int 1989, 44:367-381.
25. Aloia J.F., Arunabh-Talwar S., Pollack S., Yeh J.K. The remodeling transient and the calcium economy. Osteoporos Int 2008, 19:1001-1009.
26. Kimmel D.B., Recker R.R., Gallagher J.C., Vaswani A.S., Aloia J.F. A comparison of iliac bone histomorphometric data in post-menopausal osteoporotic and normal subjects. Bone Miner 1990, 11:217-235.
27. Kostenuik P.J., Smith S.Y., Jolette J., Schroeder J., Pyrah I., Ominsky M.S. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone 2011, 49:151-161.
28. Brockstedt H., Kassem M., Eriksen E.F., Mosekilde L., Melsen F. Age- and sex-related changes in iliac cortical bone mass and remodeling. Bone 1993, 14:681-691.
29. Compston J.E., Vedi S., Kaptoge S., Seeman E. Bone remodeling rate and remodeling balance are not co-regulated in adulthood: implications for the use of activation frequency as an index of remodeling rate. J Bone Miner Res 2007, 22:1031-1036.
30. Eriksen E.F., Hodgson S.F., Eastell R., Cedel S.L., O'Fallon W.M., Riggs B.L. Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J Bone Miner Res 1990, 5:311-319.
31. Jilka R.L., Weinstein R.S., Takahashi K., Parfitt A.M., Manolagas S.C. Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J Clin Invest 1996, 97:1732-1740.
32. Li C.Y., Price C., Delisser K., Nasser P., Laudier D., Clement M., et al. Long-term disuse osteoporosis seems less sensitive to bisphosphonate treatment than other osteoporosis. J Bone Miner Res 2005, 20:117-124.
33. Saffar J.L., Lasfargues J.J., Cherruau M. Alveolar bone and the alveolar process: the socket that is never stable. Periodontoly 2000 1997, 2000(13):76-90.
34. King G.J., Latta L., Rutenberg J., Ossi A., Keeling S.D. Alveolar bone turnover in male rats: site- and age-specific changes. Anat Rec 1995, 242:321-328.
35. Parfitt A.M. Morphological basis of bone mineral measurements: transient and steady state effects of treatment in osteoporosis. Miner Electrolyte Metabol 1980, 4:273-287.
36. Heaney R.P. The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 1994, 9:1515-1523.
37. Shahnazari M., Dwyer D., Chu V., Asuncion F., Stolina M., Ominsky M., et al. Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice. Bone 2012, 50:628-637.
38. Colman R.J., Lane M.A., Binkley N., Wegner F.H., Kemnitz J.W. Skeletal effects of aging in male rhesus monkeys. Bone 1999, 24:17-23.
39. Recker R.R., Davies K.M., Hinders S.M., Heaney R.P., Stegman M.R., Kimmel D.B. Bone gain in young adult women. JAMA 1992, 268:2403-2408.
40. Gilsanz V., Gibbens D.T., Carlson M., Boechat M.I., Cann C.E., Schulz E.E. Peak trabecular vertebral density: a comparison of adolescent and adult females. Calcif Tissue Int 1988, 43:260-262.
41. Painter S.E., Kleerekoper M., Camacho P.M. Secondary osteoporosis: a review of the recent evidence. Endocr Pract 2006, 12:436-445.
42. Alper J. Rethinking Neanderthals. Smithsonian Magazine 2003, [June].
43. Currey J.D., Alexander R.M. The thickness of the walls of tubular bones. J Zool Lond 1985, 206A:453-468.
44. Frost H.M. Bone "mass" and the "mechanostat": a proposal. Anat Rec 1987, 219:1-9.
45. Wang Q., Xu L., Wang Q., Chen D., Tian H., Lu C., et al. Is bone loss the reversal of bone accrual? evidence from a cross-sectional study in daughter-mother-grandmother trios. J Bone Miner Res 2011, 26:934-940.
46. Young D.R., Niklowitz W.J., Brown R.J., Jee W.S. Immobilization-associated osteoporosis in primates. Bone 1986, 7:109-117.
47. Morey E.R., Baylink D.J. Inhibition of bone formation during space flight. Science 1978, 201:1138-1141.
48. Yeh J.K., Liu C.C., Aloia J.F. Effect of exercise and immobilization on bone formation and resorption in young rats. Am J Physiol 1993, 264:182-189.
49. Swift J.M., Swift S.N., Nilsson M.I., Hogan H.A., Bouse S.D., Bloomfield S.A. Cancellous bone formation response to simulated resistance training during disuse is blunted by concurrent alendronate treatment. J Bone Miner Res 2011, 26:2140-2150.
50. Uhthoff H.K., Jaworski Z.F. Bone loss in response to long-term immobilisation. J Bone Jt Surg Br 1978, 60-B:420-429.
51. Bagi C.M., Miller S.C. Comparison of osteopenic changes in cancellous bone induced by ovariectomy and/or immobilization in adult rats. Anat Rec 1994, 239:243-254.
52. Wronski T.J., Morey E.R. Inhibition of cortical and trabecular bone formation in the long bones of immobilized monkeys. Clin Orthop Relat Res 1983, 181:269-276.
53. Minaire P., Neunier P., Edouard C., Bernard J., Courpron P., Bourret J. Quantitative histological data on disuse osteoporosis: comparison with biological data. Calcif Tissue Res 1974, 17:57-73.
54. Li C.Y., Majeska R.J., Laudier D.M., Mann R., Schaffler M.B. High-dose risedronate treatment partially preserves cancellous bone mass and microarchitecture during long-term disuse. Bone 2005, 37:287-295.
55. Gaudio A., Pennisi P., Bratengeier C., Torrisi V., Lindner B., Mangiafico R.A., et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 2010, 95:2248-2253.
56. Zehnder Y., Luthi M., Michel D., Knecht H., Perrelet R., Neto I., et al. Long-term changes in bone metabolism, bone mineral density, quantitative ultrasound parameters, and fracture incidence after spinal cord injury: a cross-sectional observational study in 100 paraplegic men. Osteoporos Int 2004, 15:180-189.
57. Campbell G.M., Ominsky M.S., Boyd S.K. Bone quality is partially recovered after the discontinuation of RANKL administration in rats by increased bone mass on existing trabeculae: an in vivo micro-CT study. Osteoporos Int 2011, 22:931-942.
58. Parfitt A.M. Age-related structural changes in trabecular and cortical bone: cellular mechanisms and biomechanical consequences. Calcif Tissue Int 1984, 36(Suppl. 1):S123-S128.
59. Borah B., Dufresne T., Nurre J., Phipps R., Chmielewski P., Wagner L., et al. Risedronate reduces intracortical porosity in women with osteoporosis. J Bone Miner Res 2010, 25:41-47.
60. Zebaze R., Ghasem-Zadeh A., Boyte A., Iuliano-Burns S., Mirams M., Price R.I., et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 2010, 375:1729-1736.
61. Mosekilde L. Consequences of the remodelling process for vertebral trabecular bone structure: a scanning electron microscopy study uncoupling of unloaded structures. Bone Miner. 1990, 10:13-35.
62. van Oers R.F., van Rietbergen B., Ito K., Huiskes R., Hilbers P.A. Simulations of trabecular remodeling and fatigue: is remodeling helpful or harmful?. Bone 2011, 48:1210-1215.
63. Gerson A.R., Guglielmo C.G. Flight at low ambient humidity increases protein catabolism in migratory birds. Science 2011, 333:1434-1436.
64. Guerreiro P.M., Renfro J.L., Power D.M., Canario A.V. The parathyroid hormone family of peptides: structure, tissue distribution, regulation, and potential functional roles in calcium and phosphate balance in fish. Am J Physiol Regul Integr Comp Physiol 2007, 292:R679-R696.
65. Suzuki N., Danks J.A., Maruyama Y., Ikegame M., Sasayama Y., Hattori A., et al. Parathyroid hormone 1 (1-34) acts on the scales and involves calcium metabolism in goldfish. Bone 2011, 48:1186-1193.
66. Srivastav A.K., Das V.K., Srivastav S.K., Suzuki N. Amphibian calcium regulation: physiological aspects. Zooligica Poloniae 2000, 45:9-36.
67. Glazer L., Shechter A., Tom M., Yudkovski Y., Weil S., Aflalo E.D., et al. A protein involved in the assembly of an extracellular calcium storage matrix. J Biol Chem 2010, 285:12831-12839.
68. Lieben L., Masuyama R., Torrekens S., Van Looveren R., Schrooten J., Baatsen P., et al. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. J Clin Invest 2012, 122:1803-1815.
69. Thomas M.L., Ibarra M.J., Solcher B., Wetzel S., Simmons D.J. The effect of low dietary calcium and calcium supplementation on calcium metabolism and bone in the immature, growing Rat. Bone Miner 1988, 4:73-82.
70. Brommage R., DeLuca H.F. Regulation of bone mineral loss during lactation. Am J Physiol 1985, 248:E182-E187.
71. Takagi Y., Yamada J. Effect of calcium deprivation on the metabolism of acellular bone in tilapia, oreochromis niloticus. Comp Biochem Physiol 1992, 102A:481-485.
72. Takagi Y., Yamada J. Changes in metabolism of acellular bone in tilapia, oreochromis niloticus, during deficiency and subsequent repletion of calcium. Comp Biochem Physiol 1993, 105A:459-462.
73. Shapiro R., Heaney R.P. Co-dependence of calcium and phosphorus for growth and bone development under conditions of varying deficiency. Bone 2003, 32:532-540.
74. Zegels B., Eastell R., Russell R., Ethgen D., Roumagnac I., Collette J., et al. Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis. Bone 2001, 28:108-112.
75. Shapses S.A., Kendler D., Robson R., Hansen K.E., Sherrel R., Field M.P., et al. Effect of alendronate and vitamin D(3) on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women. J Bone Miner Res 2011, 26:1836-1844.
76. Zikan V., Stepan J.J. Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone. Bone 2009, 44:634-638.
77. Lees C.J., Jerome C.P., Register T.C., Carlson C.S. Changes in bone mass and bone biomarkers of cynomolgus monkeys during pregnancy and lactation. J Clin Endocrinol Metab 1998, 83:4298-4302.
78. Shen V., Birchman R., Xu R., Lindsay R., Dempster D.W. Short-term changes in histomorphometric and biochemical turnover markers and bone mineral density in estrogen- and/or dietary calcium-deficient rats. Bone 1995, 16:149-156.
79. Yuan Y.Y., Kostenuik P.J., Ominsky M.S., Morony S., Adamu S., Simionescu D.T., et al. Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease. Osteoporos Int 2008, 19:625-635.
80. Morony S., Warmington K., Adamu S., Asuncion F., Geng Z., Grisanti M., et al. The RANKL inhibitor osteoprotegerin (OPG) causes greater suppression of bone resorption and hypercalcemia compared to bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 2005, 146:3235-3243.
81. Tomoyasu A., Goto M., Fujise N., Mochizuki S., Yasuda H., Morinaga T., et al. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochem Biophys Res Commun 1998, 245:382-387.
82. Yamamoto M., Murakami T., Nishikawa M., Tsuda E., Mochizuki S., Higashio K., et al. Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat. Endocrinology 1998, 139:4012-4015.
83. Akatsu T., Murakami T., Ono K., Nishikawa M., Tsuda E., Mochizuki S.I., et al. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone 1998, 23:495-498.
84. 3. J Bone Miner Res 1999, 14:1478-1485.
85. Kostenuik P.J., Nguyen H., McCabe J., Warmington K.S., Kurahara C., Sun N., et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009, 24:182-195.
86. Brown J.P., Prince R.L., Deal C., Recker R.R., Kiel D.P., de Gregorio, et al. Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009, 24:153-161.
87. Stopeck A.T., Lipton A., Body J.J., Steger G.G., Tonkin K., de Boer, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010, 28:5132-5139.
88. Parfitt A.M. Misconceptions (3): calcium leaves bone only by resorption and enters only by formation. Bone 2003, 33:259-263.
89. Talmage R.V., Talmage D.W. Calcium homeostasis: solving the solubility problem. J Musculoskelet Neuronal Interact 2006, 6:402-407.
90. Miller S.C. Rapid activation of the medullary bone osteoclast cell surface by parathyroid hormone. J Cell Biol 1978, 76:615-618.
91. Okazaki M., Ferrandon S., Vilardaga J.P., Bouxsein M.L., Potts J.T., Gardella T.J. Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation. Proc Natl Acad Sci U S A 2008, 105:16525-16530.
92. Burgess T., Qian Y.X., Kaufman S., Ring B.D., Van G., Capparelli C., et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999, 145:527-538.
93. Lacey D.L., Tan H.L., Lu J., Kaufman S., Van G., Qiu W., et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000, 157:435-448.
94. Sipos W., Zysset P., Kostenuik P., Mayrhofer E., Bogdan C., Rauner M., et al. OPG-Fc treatment in growing pigs leads to rapid reductions in bone resorption markers, serum calcium, and bone formation markers. Horm Metab Res 2011, 43:944-949.
95. Bekker P.J., Holloway D.L., Rasmussen A.S., Murphy R., Martin S.W., Leese P.T., et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004, 19:1059-1066.
96. Fizazi K., Bosserman L., Gao G., Skacel T., Markus R. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 2009, 182:509-516.
97. Ominsky M.S., Kostenuik P.J., Cranmer P., Smith S.Y., Atkinson J.E. The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young intact cynomolgus monkeys. Osteoporos Int 2007, 18:1073-1082.
98. Ominsky M.S., Stouch B., Schroeder J., Pyrah I., Stolina M., Smith S.Y., et al. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone 2011, 49:162-173.
99. Qing H., Ardeshirpour L., Pajevic P.D., Dusevich V., Jähn K., Kato S., et al. Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J Bone Miner Res 2012, 27:1018-1029.
100. Tordoff M.G., Shao H., Alarcon L.K., Margolskee R.F., Mosinger B., Bachmanov A.A., et al. Involvement of T1R3 in calcium-magnesium taste. Physiol Genomics 2008, 34:338-348.
101. Ohsu T., Amino Y., Nagasaki H., Yamanaka T., Takeshita S., Hatanaka T., et al. Involvement of the calcium-sensing receptor in human taste perception. J Biol Chem 2010, 285:1016-1022.
102. Stini W.A. Calcium homeostasis and human evolution. Coll Antropol 1988, 22:411-425.
103. Abrams S.A., Griffin I.J., Hicks P.D., Gunn S.K. Pubertal girls only partially adapt to low dietary calcium intakes. J Bone Miner Res 2004, 19:759-763.
104. Brommage R., DeLuca H.F. Self-selection of a high calcium diet by vitamin D-deficient lactating rats increases food consumption and milk production. J Nutr 1984, 114:1377-1385.
105. Bilezikian J.P., Khan A., Potts J.T., Brandi M.L., Clarke B.L., Shoback D., et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res 2011, 26:2317-2337.
106. Barry D.W., Hansen K.C., van Pelt R.E., Witten M., Wolfe P., Kohrt W.M. Acute calcium ingestion attenuates exercise-induced disruption of calcium homeostasis. Med Sci Sports Exerc 2011, 43:617-623.
107. Rosen C.J., Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med 2003, 348:1503-1504.
108. Yarrington J.T., Capen C.C., Black H.E., Re R., Potts J.T., Geho W.B. Experimental parturient hypocalcemia in cows following pepartal chemical inhibition of bone resorption. Am J Pathol 1976, 83:569-588.
109. Guerrini M.M., Sobacchi C., Cassani B., Abinun M., Kilic S.S., Pangrazio A., et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNRSF11A (RANK) mutations. Am J Hum Genet 2008, 83:64-76.
110. Block G.A., Bone H.G., Fang L., Lee E., Padhi D. A single-dose stud of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012, 27:1471-1479.
111. Kurz P., Monier-Faugere M.C., Bognar B., Werner E., Roth P., Vlachojannis J., et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994, 46:855-861.
112. Brasier A.R., Nussbaum S.R. Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med 1988, 84:654-660.
113. Onal M., Galli C., Fu Q., Xiong J., Weinstein R.S., Manolagas S.C., et al. The RANKL distal control region is required for the increase in RANKL expression, but not the bone loss, associated with hyperparathyroidism or lactation in adult mice. Mol Endocrinol 2011, 26:341-348.
114. Bae Y.J., Kim M.H. Calcium and magnesium supplementation improves serum OPG/RANKL in calcium-deficient ovariectomized rats. Calcif Tissue Int 2010, 87:365-372.
115. Lloyd S.A., Yuan Y.Y., Kostenuik P.J., Ominsky M.S., Lau A.G., Morony S., et al. Soluble RANKL induces high bone turnover and decreases bone volume, density and strength in mice. Calcif Tissue Int 2008, 82:361-372.
116. Enomoto T., Furuya Y., Tomimori Y., Mori K., Miyazaki J., Yasuda H. Establishment of a new murine model of hypercalcemia with anorexia by overexpression of soluble receptor activator of NF-kappaB ligand using an adenovirus vector. J Bone Miner Metab 2011, 29:414-421.
117. Erben R.G. Trabecular and endocortical bone surfaces in the rat: modeling or remodeling?. Anat Rec 1996, 246:39-46.
118. Nakamura M., Udagawa N., Matsuura S., Mogi M., Nakamura H., Horiuchi H., et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 2003, 144:5441-5449.
119. Nagaraja S., Couse T.L., Guldberg R.E. Trabecular bone microdamage and microstructural stresses under uniaxial compression. J Biomech 2005, 38:707-716.
120. McNamara L.M., Van der Linden J.C., Weinans H., Prendergast P.J. Stress-concentrating effect of resorption lacunae in trabecular bone. J Biomech 2006, 39:734-741.
121. Busse B., Hahn M., Saltau M., Zustin J., Püschel K., Duda G.N., et al. Increased calcium content and inhomogeneity of mineralization render bone toughness in osteoporosis: mineralization, morphology and biomechanics of human single trabeculae. Bone 2009, 45:1034-1043.
122. van der Linden J.C., Homminga J., Verhaar J., Weinans H. Mechanical consequences of bone loss in cancellous bone. J Bone Miner Res 2001, 16:457-465.
123. Slyfield C.R., Tkachenko E.V., Fischer S.E., Ehlert K.M., Yi I.H., Jekir M.G., et al. Mechanical failure begins preferentially near resorption cavities in human vertebral cancellous bone under compression. Bone 2012, 50:1281-1287.
124. Kostenuik P.J., Capparelli C., Morony S., Adamu S., Shimamoto G., Shen V., et al. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 2001, 142:4295-4305.
125. Bullamore J.R., Wilkinson R., Gallagher J.C., Nordin B.E., Marshall D.H. Effect of age on calcium absorption. Lancet 1970, 2:535-537.
126. McKane W.R., Khosla S., Egan K.S., Robins S.P., Burritt M.F., Riggs B.L. Role of calcium intake in modulating age-related increases in parathyroid function and bone resorption. J Clin Endocrinol Metab 1996, 81:1699-1703.
127. Reid I.R., Mason B., Horne A., Ames R., Reid H.E., Bava U., et al. Randomized controlled trial of calcium in healthy older women. Am J Med 2006, 119:777-785.
128. Dibba B., Prentice A., Ceesay M., Stirling D.M., Cole T.J., Poskitt E. Effect of calcium supplementation on bone mineral accretion in Gambian children accustomed to a low-calcium diet. Am J Clin Nutr 2000, 71:544-549.
129. Iwamoto J., Takeda T., Sato Y., Yeh J.K. Response of cortical and cancellous bones to mild calcium deficiency in young growing female rats: a bone histomorphometry study. Exp Anim 2004, 53:347-354.
130. Seto H., Aoki K., Kasugai S., Ohya K. Trabecular bone turnover, bone marrow cell development, and gene expression of bone matrix proteins after low calcium feeding in rats. Bone 1999, 25:687-695.
131. Garner S.C., Peng T.-C., Toverud S.U. Modulation of serum parathyroid hormone and ionized calcium concentrations during reproduction in rats fed a low calcium diet. J Bone Miner Res 1988, 3. 319-232.
132. Anderson J.J., Garner S.C., Mar M.H., Boass A., Toverud S.U., Parikh I. The ovariectomized, lactating rat as an experimental model for osteopenia: calcium metabolism and bone changes. Bone Miner 1990, 11:43-53.
133. Garner S.C., Anderson J.J., Mar M.H., Parikh I. Estrogens reduce bone loss in the ovariectomized, lactating rat model. Bone Miner 1991, 15:19-31.
134. Miao D., Li J., Xue Y., Su H., Karaplis A.C., Goltzman D. Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. Endocrinology 2004, 145:3554-3562.
135. Galli C., Zella L.A., Fretz J.A., Fu Q., Pike J.W., Weinstein R.S., et al. Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass. Endocrinology 2008, 149:146-153.
136. Heaney R.P. Is the paradigm shifting?. Bone 2003, 33:457-465.
137. Fleet J. How well you absorb calcium is important for limiting hip fracture risk. Nutr Rev 2001, 59:338-341.
138. Ensrud K.E., Duong T., Cauley J.A., Heaney R.P., Wolf R.L., Harris E., et al. Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Study of Osteoporotic Fractures Research Group. Ann Intern Med 2000, 132:345-353.
139. Chen C., Kalu D.N. Strain differences in bone density and calcium metabolism between C3H/HeJ and C57BL/6J mice. Bone 1999, 25:413-420.
140. Li C.Y., Schaffler M.B., Wolde-Semait H.T., Hernandez J., Jepsen K.J. Genetic background influences cortical bone resorption to ovariectomy. J Bone Miner Res 2005, 20:2150-2158.
141. Niedzwiedzki G., Szrek P., Narkiewicz K., Narkiewicz M., Ahlberg P.E. Tetrapod trackways from the early Middle Devonian period of Poland. Nature 2010, 463:43-48.
142. Ahlberg P.E., Milner A.R. The origin and early diversification of tetrapods. Nature 1994, 368:507-514.
143. Yoshida R., Talmage R.V. Removal of calcium from frog bone by periotoneal lavage, a study of parathyroid hormone function in amphibians. Gen Comp Endocr 1962, 2:551-557.
144. Sire Y.-V., Hyusseune A., Meunier F.J. Osteoclasts in teloest fish: light- and electron-microscopical observations. Cell Tissue Res 1990, 260:85-94.
145. Moss M.L. Studies of the acellular bone of teleost fish. Acta Anat 1965, 60:262-276.
146. Nemoto Y., Higuchi K., Baba O., Kudo A., Takano Y. Multinucleate osteoclasts in medaka as evidence of active bone remodeling. Bone 2007, 40:399-408.
147. Matsushiro A., Miyashita T. Evolution of hard-tissue mineralization: comparison of the inner skeletal system and the outer shell system. J Bone Miner Metab 2004, 22:163-169.
148. Parfitt A.M. Bone remodeling: relationships to amount and structure of bone, and the pathogenesis and prevention of fractures. Osteoporosis, Etiology, Diagnosis, and Management 1988, 45-93. Raven Press, New York. B.L. Riggs, L.J. Melton (Eds.).
149. Kwiecinski G.G., Krook L., Wimsatt W.A. Annual skeletal changes in the little brown bat, Myotis lucifugus lucifugus, with particular reference to pregnancy and lactation. Am J Anat 1987, 178:410-420.
150. Burr D.B. Remodeling and the repair of fatigue damage. Calcif Tissue Int 1993, 53(Suppl. 1):S75-S81.
151. Parfitt A.M. What is the normal rate of bone remodeling?. Bone 2004, 35:1-3.
152. Martin R.B. Is all cortical bone remodeling initiated by microdamage?. Bone 2002, 30:8-13.
153. de Buffrenil V., Schoevaert D. On how the periosteal bone of the delphinid humerus becomes cancellous: ontogeny of a histological specialization. J Morphol 1988, 198:149-164.
154. Bell K.L., Loveridge N., Jordan G.R., Power J., Constant C.R., Reeve J. A novel mechanism for induction of increased cortical porosity in cases of intracapsular hip fracture. Bone 2000, 27:297-304.
155. Turner C.H. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 2002, 13:97-104.
156. Burr D.B., Hirano T., Turner C.H., Hotchkiss C., Brommage R., Hock J.M. Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001, 16:157-165.
157. Currey J.D. The effect of porosity and mineral content on the Young's modulus of elasticity of compact bone. J Biomech 1988, 21:131-139.
158. Flora L., Hassing G.S., Parfitt A.M., Villaneuva A.R. Comparative skeletal effects of two diphosphonates in dogs. Metab Bone Dis Rel Res 1980, 2S:389-407.
159. Hirano T., Turner C.H., Forwood M.R., Johnston C.C., Burr D.B. Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation?. Bone 2000, 27:13-20.
160. Mashiba T., Turner C.H., Hirano T., Forwood M.R., Jacob D.S., Johnston C.C., et al. Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures. Bone 2001, 29:271-278.
161. Lenehan T.M., Balligand M., Nunamaker D.M., Wood F.E. Effect of EHDP on fracture healing in dogs. J Orthop Res 1985, 3:499-507.
162. de Buffrenil V., Francillon-Vieillot H. Ontogenetic changes in bone compactness in male and female Nile monitors (Varanus niloticus). J Zool Lond 2001, 254:539-546.
163. Schweitzer M.H., Wittmeyer J.L., Horner J.R. Gender-specific reproductive tissue in ratites and Tyrannosaurus rex. Science 2005, 308:1456-1460.
164. Miller S.C., Bowman B.M. Medullary bone osteogenesis following estrogen administration to mature male Japanese quail. Dev Biol 1981, 87:52-63.
165. Fleming R.H., McCormack H.A., McTeir L., Whitehead C.C. Medullary bone and humeral breaking strength in laying hens. Res Vet Sci 1998, 64:63-67.
166. Miller S.C. Calcium homeostasis and mineral turnover in the laying hen. Bone Biology and Skeletal Disorders in Poultry 1992, 103-116. Butterworth and Heinemann, Oxford. C.C. Whitehead (Ed.).
167. Dobnig H., Kainer F., Stepan V., Winter R., Lipp R., Schaffer M., et al. Elevated parathyroid hormone-related peptide levels after human gestation: relationship to changes in bone and mineral metabolism. J Clin Endocrinol Metab 1995, 80:3699-3707.
168. Carneiro R.M., Prebehalla L., Tedesco M.B., Sereika S.M., Hugo M., Hollis B.W., et al. Lactation and bone turnover: a conundrum of marked bone loss in the setting of coupled bone turnover. J Clin Endocrinol Metab 2010, 95:1767-1776.
169. Bezerra F.F., Laboissiere F.P., King J.C., Donangelo C.M. Pregnancy and lactation affect markers of calcium and bone metabolism differently in adolescent and adult women with low calcium intakes. J Nutr 2002, 132:2183-2187.
170. Miller S.C., Shupe J.G., Redd E.H., Miller M.A., Omura T.H. Changes in bone mineral and bone formation rates during pregnancy and lactation in rats. Bone 1986, 7:283-287.
171. Vajda E.G., Kneissel M., Muggenburg B., Miller S.C. Increased intracortical bone remodeling during lactation in beagle dogs. Biol Reprod 1999, 61:1439-1444.
172. Kalkwarf H.J. Hormonal and dietary regulation of changes in bone density during lactation and after weaning in women. J Mammary Gland Biol Neoplasia 1999, 4:319-321.
173. Laskey M.A., Prentice A., Hanratty L.A., Jarjou L.M., Dibba B., Beavan S.R., et al. Bone changes after 3 mo of lactation: influence of calcium intake, breast-milk output, and vitamin D-receptor genotype. Am J Clin Nutr 1998, 67:685-692.
174. Kalkwarf H.J., Specker B.L., Bianchi D.C., Ranz J., Ho M. The effect of calcium supplementation on bone density during lactation and after weaning. N Engl J Med 1997, 337:523-528.
175. Hopkinson J.M., Butte N.F., Ellis K., Smith E.O. Lactation delays postpartum bone mineral accretion and temporarily alters its regional distribution in women. J Nutr 2000, 130:777-783.
176. Wysolmerski J.J. The evolutionary orgins of maternal calcium and bone metabolism during lactation. J Mammary Gland Biol Neoplasia 2002, 7:267-276.
177. Miller S.C., Bowman B.M. Comparison of bone loss during normal lactation with estrogen deficiency osteopenia and immobilization osteopenia in the rat. Anat Rec 1998, 251:265-274.
178. VanHouten J.N., Wysolmerski J.J. Low estrogen and high parathyroid hormone-related peptide levels contribute to accelerated bone resorption and bone loss in lactating mice. Endocrinology 2003, 144:5521-5529.
179. Vajda E.G., Bowman B.M., Miller S.C. Cancellous and cortical bone mechanical properties and tissue dynamics during pregnancy, lactation and postlactation in the rat. Biol Reprod 2001, 65:689-695.
180. Kovacs C.S. Calcium and bone metabolism in pregnancy and lactation. J Clin Endocrinol Metab 2001, 86:2344-2348.
181. Prentice A., Jarjou L.M., Stirling D.M., Buffenstein R., Fairweather-Tait S. Biochemical markers of calcium and bone metabolism during 18 months of lactation in Gambian women accustomed to a low calcium intake and in those consuming a calcium supplement. J Clin Endocrinol Metab 1998, 83:1059-1066.
182. Quan-Sheng D., Miller S.C. Calciotropic hormone levels and calcium absorption during pregnancy in rats. Am J Physiol 1989, 257:E118-E123.
183. Ritchie L.D., Fung E.B., Halloran B.P., Turnlund J.R., Van Loan M.D., Cann C. A longitudinal study of calcium homeostasis during human pregnancy and lactation and after resumption of menses. Am J Clin Nutr 1998, 67:693-701.
184. Black A.J., Topping J., Durham B., Farquharson R.G., Fraser W.D. A detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy. J Bone Miner Res 2000, 15:557-563.
185. Sowers M., Zhang D., Hollis B.W., Shapiro B., Janney C.A., Crutchfield M., et al. Role of calciotrophic hormones in calcium mobilization of lactation. Am J Clin Nutr 1998, 67:284-291.
186. Cross N.A., Hillman L.S., Allen S.H., Krause G.F., Vieira N.E. Calcium homeostasis and bone metabolism during pregnancy, lactation, and postweaning: a longitudinal study. Am J Clin Nutr 1995, 61:514-523.
187. Horwitz M.J., Tedesco M.B., Sereika S.M., Hollis B.W., Garcia-Ocana A., Stewart A.F. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab 2003, 88:1603-1609.
188. Peng T.C., Garner S.C., Kusy R.P., Hirsch P.F. Effect of number of suckling pups and dietary calcium on bone mineral content and mechanical properties of femurs of lactating rats. Bone Miner 1988, 3:293-304.
189. Miller M.A., Omura T.H., Miller S.C. Increased cancellous bone remodeling during lactation in beagles. Bone 1989, 10:279-285.
190. Bowman B.M., Siska C.C., Miller S.C. Greatly increased cancellous bone formation with rapid improvements in bone structure in the rat maternal skeleton after lactation. J Bone Miner Res 2002, 17:1954-1960.
191. Miller S.C., Bowman B.M. Rapid improvements in cortical bone dynamics and structure after lactation in established breeder rats. Anat Rec 2004, 276A:143-149.
192. Miller S.C., Bowman B.M. Rapid inactivation and apoptosis of osteoclasts in the maternal skeleton during the bone remodeling reversal at the end of lactation. Anat Rec 2007, 290:65-73.
193. Yoshinaga K., Hawkins R.A., Stocker J.F. Estrogen secretion by the rat ovary in vivo during the estrous cycle and pregnancy. Endocrinology 1969, 85:103-112.
194. Eghbali-Fatourechi G., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., Riggs B.L. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003, 111:1221-1230.
195. Ardeshirpour L., Dann P., Adams D.J., Nelson T., Van Houten J., Horowitz M.C., et al. Weaning triggers a decrease in receptor activator of nuclear factor-kappaB ligand expression, widespread osteoclast apoptosis, and rapid recovery of bone mass after lactation in mice. Endocrinology 2007, 148:3875-3886.
196. Riches P.L., McRorie E., Fraser W.D., Determann C., van't Hof R., Ralston S.H. Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin. N Engl J Med 2009, 361:1459-1465.
197. Miller S.C., Anderson B.L., Bowman B.M. Weaning initiates a rapid and powerful anabolic phase in the rat maternal skeleton. Biol Reprod 2005, 73:156-162.
198. Recker R., Lappe J., Davies K.M., Heaney R. Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 2004, 19:1628-1633.
199. Williams G.C. Pleiotropy, natural selection and the evolution of senescence. Evolution 1957, 11:398-411.
200. Burger H.G., Dudley E.C., Robertson D.M., Dennerstein L. Hormonal changes in the menopause transition. Rec Prog Horm Res 2002, 57:257-275.
201. Sowers M.R., Zheng H., McConnell D., Nan B., Harlow S.D., Randolph J., et al. Estradiol rates of change in relation to the final menstrual period in a population-based cohort of women. J Clin Endocrinol Metab 2008, 93:3847-3852.
202. Pollycove R., Naftolin F., Simon J.A. The evolutionary origin and significance of menopause. Menopause 2011, 18:336-342.
203. Bowman B.M., Miller S.C. Skeletal adaptations during mammalian reproduction. J Musculoskel Neuron Interact 2001, 1:347-355.
204. Garnero P., Sornet-Rendu E., Chapuy M.C., Delmas P.D. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996, 11:337-349.
205. Jerome C.P., Turner C.H., Lees C.J. Decreased bone mass and strength in ovariectomized cynomoglus monkeys (macaca fascicularis). Calcif. Tissue Int 1997, 60:265-270.
206. Kennedy O.D., Brennan O., Rackard S.M., Staines A., O'Brien F.J., Taylor D., et al. Effects of ovariectomy on bone turnover, porosity, and biomechanical properties in ovine compact bone 12 months postsurgery. J Orthop Res 2009, 27:303-309.
207. Sowers M.R., Zheng H., Jannausch M.L., McConnell D., Nan B., Harlow S., et al. Amount of bone loss in relation to time around the final menstrual period and follicle-stimulating hormone staging of the transmenopause. J Clin Endocrinol Metab 2010, 95:2155-2162.
208. Nicks K.M., Fowler T.W., Gaddy D. Reproductive hormones and bone. Curr Osteoporos Rep 2010, 8:60-67.
209. Kovacs C.S. Calcium and bone metabolism during pregnancy and lactation. J Mammary Gland Biol Neoplasia 2005, 10:105-118.
210. Neville M.C., McFadden T.B., Forsyth I. Hormonal regulation of mammary differentiation and milk secretion. J Mammary Gland Biol Neoplasia 2002, 7:49-66.
211. Seriwatanachai D., Thongchote K., Charoenphandhu N., Pandaranandaka J., Tudpor K., Teerapornpuntakit J., et al. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone 2008, 42:535-546.
212. Krishnamra N., Seemoung J. Effects of acute and long-term administration of prolactin on bone 45Ca uptake, calcium deposit, and calcium resorption in weaned, young, and mature rats. Can J Physiol Pharmacol 1996, 74:1157-1165.
213. Pahuja D.N., DeLuca H.F. Stimulation of intestinal calcium transport and bone calcium mobilization by prolactin in vitamin D-deficient rats. Science 1981, 214:1038-1039.
214. Lippuner K., Zehnder H.J., Casez J.P., Takkinen R., Jaeger P. PTH-related protein is released into the mother's bloodstream during location: evidence for beneficial effects on maternal calcium-phosphate metabolism. J Bone Miner Res 1996, 11:1394-1399.
215. Sowers M.F., Hollis B.W., Shapiro B., Randolph J., Janney C.A., Zhang D., et al. Elevated parathyroid hormone-related peptide associated with lactation and bone density loss. JAMA 1996, 276:549-554.
216. VanHouten J.N., Dann P., Stewart A.F., Watson C.J., Pollak M., Karaplis A.C., et al. Mammary-specific deletion of parathyroid hormone-related protein preserves bone mass during lactation. J Clin Invest 2003, 112:1429-1436.
217. Nordin B.E. Calcium homeostasis. Clin Biochem 1990, 23:3-10.
218. Clark M.K., Sowers M., Nichols S., Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril 2004, 82:1580-1586.
219. Riis B.J., Christiansen C., Johansen J.S., Jacobson J. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?. J Clin Endocrinol Metab 1990, 70:920-924.
220. Sowers M. Pregnancy and lactation as risk factors for subsequent bone loss and osteoporosis. J Bone Miner Res 1996, 11:1052-1060.
221. Naylor K.E., Rogers A., Fraser R.B., Hall V., Eastell R., Blumsohn A. Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. J Clin Endocrinol Metab 2003, 88:5361-5365.
222. Perrien D.S., Achenbach S.J., Bledsoe S.E., Walser B., Suva L.J., Khosla S., et al. Bone turnover across the menopause transition: correlations with inhibins and follicle-stimulating hormone. J Clin Endocrinol Metab 2006, 91:1848-1854.
223. Taxel P., Kaneko H., Lee S.K., Aguila H.L., Raisz L.G., Lorenzo J.A. Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study. Osteoporos Int 2008, 19:193-199.
224. Most W., Schot L., Ederveen A., Wee-Pals L., Papapoulos S., Lowik C. In vitro and ex vivo evidence that estrogens suppress increased bone resorption induced by ovariectomy or PTH stimulation through an effect on osteoclastogenesis. J Bone Miner Res 1995, 10:1523-1530.
225. Cheung A.M., Tile L., Cardew S., Pruthi S., Robbins J., Tomlinson G., et al. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol 2012, 13:275-284.
226. Brommage R., Hotchkiss C.E., Lees C.J., Stancill M.W., Hock J.M., Jerome C.P. Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys. J Clin Endocrinol Metab 1999, 84:3757-3763.
227. Balena R., Toolan B.C., Shea M., Markatos A., Myers E.R., Lee S.C., et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993, 92:2577-2586.
228. Thompson D.D., Seedor J.G., Quartuccio H., Solomon H., Fioravanti C., Davidson J., et al. The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons. J Bone Miner Res 1992, 7:951-960.
229. Frost H.M. Presence of microscopic cracks in vivo in bone. Henry Ford Hosp Med Bull 1960, 8:25-35.
230. Qiu S., Rao D.S., Fyhrie D.P., Palnitkar S., Parfitt A.M. The morphological association between microcracks and osteocyte lacunae in human cortical bone. Bone 2005, 37:10-15.
231. Kennedy O.D., Brennan O., Mauer P., Rackard S.M., O'Brien F.J., Taylor D., et al. The effects of increased intracortical remodeling on microcrack behaviour in compact bone. Bone 2008, 43:889-893.
232. Donahue S.W., Sharkey N.A., Modanlou K.A., Sequeira L.N., Martin R.B. Bone strain and microcracks at stress fracture sites in human metatarsals. Bone 2000, 27:827-833.
233. Allen M.R., Burr D.B. Skeletal microdamage: less about biomechanics and more about remodeling. Clinic Rev Bone Miner Metab 2008, 6:24-30.
234. Komatsubara S., Mori S., Mashiba T., Ito M., Li J., Kaji Y., et al. Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 2003, 18:512-520.
235. Komatsubara S., Mori S., Mashiba T., Li J., Nonaka K., Kaji Y., et al. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 2004, 19:999-1005.
236. Stepan J.J., Burr D.B., Pavo I., Sipos A., Michalska D., Li J., et al. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 2007, 41:378-385.
237. Forwood M.R., Burr D.B., Takano Y., Eastman D.F., Smith P.N., Schwardt J.D. Risedronate treatment does not increase microdamage in the canine femoral neck. Bone 1995, 16:643-650.
238. Chapurlat R.D., Arlot M., Burt-Pichat B., Chavassieux P., Roux J.P., Portero-Muzy N., et al. Microcrack density and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 2007, 22:1502-1509.
239. O'Neal J.M., Diab T., Allen M.R., Vidakovic B., Burr D.B., Guldberg R.E. One year of alendronate treatment lowers microstructural stresses associated with trabecular microdamage initiation. Bone 2010, 47:241-247.
240. Wang X., Erickson A.M., Allen M.R., Burr D.B., Martin R.B., Hazelwood S.J. Theoretical model of alendronate and risedronate effects on canine vertebral remodeling and microdamage. J Biomech 2009, 42:938-944.
241. Arlot M.E., Burt-Pichat B., Roux J.P., Vashishth D., Bouxsein M.L., Delmas P.D. Microarchitecture influences microdamage accumulation in human vertebral trabecular bone. J Bone Miner Res 2008, 23:1613-1618.
242. Freeman M., Todd R.C., Pirie C.J. The role of fatigue in the pathogenesis of senile femoral neck fractures. J Bone Jt Surg 1974, 56B:698-702.
243. Zioupos P., Wang X.T., Currey J.D. The accumulation of fatigue microdamage in human cortical bone of two different ages in vitro. Clin Biomech 1996, 11:365-375.
244. Wenzel T.E., Schaffler M.B., Fyhrie D.P. In vivo trabecular microcracks in human vertebral bone. Bone 1996, 19:89-95.
245. Norman T.L., Little T.M., Yeni Y.N. Age-related changes in porosity and mineralization and in-service damage accumulation. J Biomech 2008, 41:2868-2873.
246. Danova N.A., Colopy S.A., Radtke C.L., Kalscheur V.L., Markel M.D., Vanderby R., et al. Degradation of bone structural properties by accumulation and coalescence of microcracks. Bone 2003, 33:197-205.
247. Norman T.L., Yeni Y.N., Brown C.U., Wang Z. Influence of microdamage on fracture toughness of the human femur and tibia. Bone 1998, 23:303-306.
248. Burr D.B. Targeted and nontargeted bone remodeling. Bone 2002, 30:2-4.
249. Follet H., Viguet-Carrin S., Burt-Pichat B., Dépalle B., Bala Y., Gineyts E., et al. Effects of preexisting microdamage, collagen cross-links, degree of mineralization, age, and architecture on compressive mechanical properties of elderly human vertebral trabecular bone. J Orthop Res 2011, 29:481-488.
250. Zioupos P. Accumulation of in vivo fatigue microdamage and its relation to biomechanical properties in ageing human cortical bone. J Microcsc 2001, 201:270-278.
251. Schaffler M.B., Choi K., Milgrom C. Aging and microdamage accumulation in human compact bone. Bone 1995, 17:521-525.
252. Mori S., Harruff R., Ambrosius W., Burr D.B. Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures. Bone 1997, 21:521-526.
253. Frank J.D., Ryan M., Kalscheur V.L., Ruaux-Mason C.P., Hozak R.R., Muir P. Aging and accumulation of microdamage in canine bone. Bone 2002, 30:201-206.
254. Wang X., Puram S. The toughness of cortical bone and its relationship with age. Ann Biomed Eng 2004, 32:123-135.
255. O'Brien F.J., Taylor D., Lee T.C. Microcrack accumulation at different intervals during fatigue testing of compact bone. J Biomech 2003, 36:973-980.
256. Vashishth D., Behiri J.C., Bonfield W. Crack growth resistance in cortical bone: concept of microcrack toughening. J Biomech 1997, 30:763-769.
257. Akkus O., Jepsen K.J., Rimnac C.M. Microstructural aspects of the fracture process in human cortical bone. J Mater Sci Mater Med 2000, 35:6065-6074.
258. Sobelman O.S., Gibeling J.C., Stover S.M., Hazelwood S.J., Yeh O.C., Shelton D.R., et al. Do microcracks decrease or increase fatigue resistance in cortical bone?. J Biomech 2004, 37:1295-1303.
259. Sugiyama T., Meakin L.B., Galea G.L., Jackson B.F., Lanyon L.E., Ebetino F.H., et al. Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice. Bone 2011, 49:133-139.
260. Bentolila V., Boyce T.M., Fyhrie D.P., Drumb R., Skerry T.M., Schaffler M.B. Intracortical remodeling in adult rat long bones after fatigue loading. Bone 1998, 23:275-281.
261. Burr D.B., Turner C.H., Naick P., Forwood M.R., Ambrosius W., Hasan M.S., et al. Does microdamage accumulation affect the mechanical properties of bone?. J Biomech 1998, 31:337-345.
262. Colopy S.A., Benz-Dean J., Barrett J.G., Sample S.J., Lu Y., Danova N.A., et al. Response of the osteocyte syncytium adjacent to and distant from linear microcracks during adaptation to cyclic fatigue loading. Bone 2004, 35:881-891.
263. Uthgenannt B.A., Kramer M.H., Hwu J.A., Wopenka B., Silva M.J. Skeletal self-repair: stress fracture healing by rapid formation and densification of woven bone. J Bone Miner Res 2007, 22:1548-1556.
264. Finocchietti S., Andresen T., Arendt-Nielsen L., Graven-Nielsen T. Pain evoked by pressure stimulation on the tibia bone- influence of probe diameter on tissue stress and strain. Eur J Pain 2012, 16:534-542.
265. Jimenez-Andrade J.M., Mantyh W.G., Bloom A.P., Xu H., Ferng A.S., Dussor G., et al. A phenotypically restricted set of primary afferent nerve fibers innervate the bone versus skin: therapeutic opportunity for treating skeletal pain. Bone 2010, 46:306-313.
266. Martinez M.D., Schmid G.J., McKenzie J.A., Ornitz D.M., Silva M.J. Healing of non-displaced fractures produced by fatigue loading of the mouse ulna. Bone 2010, 46:1604-1612.
267. Mosley J.R., Lanyon L.E. Strain rate as a controlling influence on adaptive modeling in response to dynamic loading of the ulna in growing male rats. Bone 1998, 4:313-318.
268. Pead M.J., Skerry T.M., Lanyon L.E. Direct transformation from quiescence to bone formation in the adult periosteum following a single brief period of bone loading. J Bone Miner Res 1988, 3:647-656.
269. Barrett J.G., Sample S.J., McCarthy J., Kalscheur V.L., Muir P., Prokuski L. Effect of short-term treatment with alendronate on ulnar bone adaptation to cyclic fatigue loading in rats. J Orthop Res 2007, 25:1070-1077.
270. Burr D.B., Forwood M.R., Fyhrie D.P., Martin R.B., Schaffler M.B., Turner C.H. Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res 1997, 12:6-12.
271. Schaffler M.B., Radin E.L., Burr D.B. Long-term fatigue behavior of compact bone at low strain magnitude and rate. Bone 1990, 11:321-326.
272. Martin B. Mathematical model for repair of fatigue damage and stress fracture in osteonal bone. J Orthop Res 1995, 13:309-316.
273. Milgrom C., Finestone A., Sharkey N., Hamel A., Mandes V., Burr D., et al. Metatarsal strains are sufficient to cause fatigue fracture during cyclic overloading. Foot Ankle Int 2002, 23:230-235.
274. Lips P., Courpron P., Meunier P.J. Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age. Calcif Tissue Res 1978, 26:13-17.
275. Darby A.J., Meunier P.J. Mean wall thickness and formation periods of trabecular bone packets in idiopathic osteoporosis. Calcif Tissue Int 1981, 33:199-204.
276. Goh S.K., Yang K.Y., Koh J., Wong M.K., Chua S.Y., Chua D., et al. Subtrochanteric insufficiency fractures in patients on alendronate. J Bone Jt Surg 2007, 89-B:349-353.
277. Kwek E., Goh S.K., Koh J., Png M.A., Howe T.S. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy. Injury 2008, 39:224-231.
278. Odvina C.V., Levy S., Rao S., Zerwekh J.E., Rao D.S. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf.) 2010, 72:161-168.
279. Giusti A., Hamdy N.A., Papapoulos S.E. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 2010, 47:169-180.
280. Visekruna M., Wilson D., McKiernan F.E. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008, 93:2948-2952.
281. Aspenberg P. Bisphosphonates and fatigure fractures. IBMS BoneKey 2009, 6:465-469.
282. Vestergaard P., Schwartz F., Rejnmark L., Mosekilde L. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int 2011, 22:993-1001.
283. Abrahamsen B., Eiken P., Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 2010, 95:5258-5265.
284. Black D.M., Kelly M.P., Genant H.K., Palermo L., Eastell R., Bucci-Rechtweg C., et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010, 362:1761-1771.
285. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24:1095-1102.
286. Pazianas M., Abrahamsen B., Wang Y., Russell R.G. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. Osteoporos Int 2012, 23:2873-2884.
287. Shane E., Burr D., Ebeling P.R., Abrahamsen B., Adler R.A., Brown T.D., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267-2294.
288. Schilcher J., Michaelsson K., Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011, 364:1728-1737.
289. Lenart B.A., Neviaser A.S., Lyman S., Chang C.C., Edobor-Osula F., Steele B., et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009, 20:1353-1362.
290. Giusti A., Hamdy N.A., Dekkers O.M., Ramautar S.R., Dijkstra S., Papapoulos S.E. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 2011, 48:966-971.
291. Feldstein A., Black D., Perrin N., Rosales A.G., Friess D., Boardman D., et al. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res 2012, 27:977-986.
292. Kim S.Y., Schneeweiss S., Katz J.N., Levin R., Solomon D.H. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res 2011, 26:993-1001.
293. Park-Wyllie L.Y., Mamdani M.M., Juurlink D.N., Hawker G.A., Gunraj N., Austin P.C., et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011, 305:783-789.
294. Wang Z., Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Miner Res 2011, 26:553-560.
295. Bala Y., Depalle B., Farlay D., Douillard T., Meille S., Follet H., et al. Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization. J Bone Miner Res 2012, 27:825-834.
296. Boskey A.L., Spevak L., Weinstein R.S. Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int 2009, 20:793-800.
297. Tang S.Y., Allen M.R., Phipps R., Burr D.B., Vashishth D. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 2009, 20:887-894.
298. Shahnazari M., Yao W., Dai W., Wang B., Ionova-Martin S.S., Ritchie R.O., et al. Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged rats. Bone 2010, 46:1267-1274.
299. Kleerekoper M., Mendlovic D.B. Sodium fluoride therapy for postmenopausal osteoporosis. Endocr Rev 1993, 14:312-323.
300. Riggs B.L., Hodgson S.F., O'Fallon W.M., Chao E., Wahner H.W., Muhs J.M., et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990, 322:802-809.
301. Jiang Y., Zhao J., van Audekercke R., Dequeker J., Geusens P. Effects of low-dose long-term sodium fluoride preventive treatment on rat bone mass and biomechanical properties. Calcif Tissue Int 1996, 58:30-39.
302. Turner C.H., Garetto L.P., Dunipace A.J., Zhang W., Wilson M.E., Grynpas M.D., et al. Fluoride treatment increases serum IGF-I, bone turnover, and bone mass, but not bone strength, in rabbits. Calcif Tissue Int 1997, 61:77-83.
303. Lafage M.H., Balena R., Battle M.A., Shea M., Seedor J.G., Klein H., et al. Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. J Clin Invest 1995, 95:2127-2133.
304. Chan M.M., Riggins R.S., Rucker R.B. Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dietary fluoride on biomechanical and morphological changes in chick bone. J Nutr 1977, 107:1747-1754.
305. Wegrzyn J., Roux J.P., Arlot M.E., Boutroy S., Vilayphiou N., Guyen O., et al. Role of trabecular microarchitecture and its heterogeneity parameters in the mechanical behavior of ex vivo human L3 vertebrae. J Bone Miner Res 2010, 25:2324-2331.
306. Bouxsein M.L., Coan B.S., Lee S.C. Prediction of the strength of the elderly proximal femur by bone mineral density and quantitative ultrasound measurements of the heel and tibia. Bone 1999, 25:49-54.
307. Smith C.B., Smith D.A. Relationships between age, mineral density and mechanical properties of human femoral compacta. Acta Orthop Scand 1976, 47:496-502.
308. Spatz H.-C., O'Leary E.J., Vincent J. Young's moduli and shear moduli in cortical bone. Royal Soc Proc Biol Sci 1996, 263:287-294.
309. Ukinc K. Severe osteomalacia presenting with multiple vertebral fractures: a case report and review of the literature. Endocrine 2009, 36:30-36.
310. Ferretti J.L., Cointry G., Capozza R., Montuori E., Roldan E., Lloret A.P. Biomechanical effects of the full range of useful doses of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) on femur diaphyses and cortical bone tissue in rats. Bone Miner. 1990, 11:111-122.
311. Reitsma P.H., Bijvoet O., Verlinden-Ooms H., Van Der Wee-Pals L. Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats. Calcif Tissue Int 1980, 32:145-157.
312. Adamson B.B., Gallacher S.J., Byars J., Ralston S.H., Boyle I.T., Boyce B.F. Mineralisation defects with pamidronate therapy for Paget's disease. Lancet 1993, 342:1459-1460.
313. Storm T., Thamsborg G., Steiniche T., Genant H.K., Sorensen O.H. Effect of intermittent cyclic etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990, 322:1265-1271.
314. Kawai M., Modder U.I., Khosla S., Rosen C.J. Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov 2011, 10:141-156.
315. Cummings S.R., Ensrud K., Delmas P.D., LaCroix A.Z., Vukicevic S., Reid D.M., et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010, 362:686-696.
316. Recker R., Stakkestad J.A., Chesnut C.H., Christiansen C., Skag A., Hoiseth A., et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004, 34:890-899.
317. Cummings S.R., San Martin J., McClung M.R., Siris E.S., Eastell R., Reid I.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756-765.
318. Smith M.R., Egerdie B., Hernández Toriz N., Feldman R., Tammela T.L., Saad F., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361:745-755.
319. Schenk R.K., Merz W.A., Muhlbauer R., Russell R., Fleisch H.A. Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (CL2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 1973, 11:196-214.
320. Glatt M., Pataki A., Blattler A., Reife R. APD longterm treatment increases bone mass and mechanical strength of femora in adult mice. Calcif Tissue Int 1986, 39(Suppl. 1):A72.
321. Toolan B.C., Shea M., Myers E.R., Borchers R.E., Seedor J.G., Quartuccio H., et al. Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats. J Bone Miner Res 1992, 7:1399-1406.
322. Geusens P., Nijs J., van der Perre G., Van Audekercke R., Lowet G., Goovaerts S., et al. Longitudinal effect of tiludronate on bone mineral density, resonant frequency, and strength in monkeys. J Bone Miner Res 1992, 7:599-609.
323. Guy J.A., Shea M., Peter C.P., Morrissey R., Hayes W.C. Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 1993, 53:283-288.
324. Lepola V.T., Hannuniemi R., Kippo K., Lauren L., Jalovaara P., Vaananen H.K. Long-term effects of clodronate on growing rat bone. Bone 1996, 18:191-196.
325. Peter C.P., Guy J., Shea M., Bagdon W., Kline W.F., Hayes W.C. Long-term safety of the aminobisphosphonate alendronate in adult dogs. 1. General safety and biomechanical properties of bone. J Pharmacol Exp Ther 1996, 276:271-276.
326. Lalla S., Hothorn L.A., Haag N., Bader R., Bauss F. Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporos Int 1998, 8:97-103.
327. Kippo K., Hannuniemi R., Lauren L., Peng Z., Kuurtamo P., Virtamo T., et al. Effect of clodronate treatment on established bone loss in ovariectomized rats. Bone 1998, 23:333-342.
328. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000, 15:613-620.
329. Mashiba T., Turner C.H., Hirano T., Forwood M.R., Johnston C.C., Burr D.B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001, 28:524-531.
330. Koivukangas A., Tuukanen J., Hannuniemi R., Jamsa T., Kippo K., Jalovaara P. Effects of long-term administration of clodronate on growing rat bone. Calcif Tissue Int 2001, 69:350-355.
331. Itoh F., Kojima M., Furihata-Komatsu H., Aoyagi S., Kusama H., Komatsu H., et al. Reductions in bone mass, structure, and strength in axial and appendicular skeletons associated with increased turnover after ovariectomy in mature cynomolgus monkeys and preventative effects of clodronate. J Bone Miner Res 2002, 17:534-543.
332. Borah B., Dufresne T.E., Chmielewski P.A., Gross G.J., Prenger M.C., Phipps R.J. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 2002, 17:1139-1147.
333. Lees C.J., Register T.C., Turner C.H., Wang T., Stancill M., Jerome C.P. Effects of Raloxifene on bone density, biomarkers, and histomorphometric and biomechanical measures in ovariectomized cynomolgus monkeys. Menopause 2002, 9:320-328.
334. Hornby S.B., Evans G.P., Hornby S.L., Pataki A., Glatt M., Green J.R. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats. Calcif Tissue Int 2003, 72:519-527.
335. Ding M., Day J.S., Burr D.B., Mashiba T., Hirano T., Weinans H., et al. Canine cancellous bone microarchitecture after one year of high-dose bisphosphonates. Calcif Tissue Int 2003, 72:737-744.
336. Smith S.Y., Recker R.R., Hannan M., Muller R., Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomogus monkeys. Bone 2003, 32:45-55.
337. Muller R., Hannan M., Smith S.Y., Bauss F. Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey. J Bone Miner Res 2004, 19:1787-1796.
338. Glatt M., Pataki A., Evans G.P., Hornby S.B., Green J.R. Loss of vertebral bone and mechanical strength in estrogen-deficient rats is prevented by long-term administration of zoledronic acid. Osteoporos Int 2004, 15:707-715.
339. Lees C.J., Ederveen A.G., Spanjers C.P., Clarkson T.B. Effects of tibolone on bone quality in ovariectomized monkeys. Menopause 2005, 12:613-618.
340. Atkinson J., Cranmer P., Saunders T., Pyrah I., Stolina M., Smith S.Y., et al. AMG 162, a fully human RANKL antibody, increases bone mass and bone strength in cynomolgus monkeys. J Bone Miner Res 2005, 20(Suppl. 1):S294.
341. Allen M.R., Iwata K., Phipps R., Burr D.B. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006, 39:872-879.
342. Allen M.R., Iwata K., Sato M., Burr D.B. Raloxifene enhances vertebral mechanical properties independent of bone density. Bone 2006, 39:1130-1135.
343. Allen M.R., Hogan H.A., Hobbs W.A., Koivuniemi A.S., Koivuniemi M.C., Burr D.B. Raloxifene enhances material-level mechanical properties of femoral cortical and trabecular bone. Endocrinology 2007, 148:3908-3913.
344. Allen M.R., Burr D.B. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 2007, 22:1759-1765.
345. Ominsky M.S., Li X., Tan H. The effects of alendronate or denosumab on cortical and trabecular bone mass, bone strength, and bone mass-strength relationships in mice. J Bone Miner Res 2008, 23(Suppl. 1):S40.
346. Gasser J.A., Ingold P., Venturiere A., Shen V., Green J.R. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res 2008, 23:544-551.
347. Ominsky M.S., Smith S.Y., Vlasseros F., Samadfam R., Kostenuik P.J. Transition from alendronate to denosumab in ovariectomized cynomolgus monkeys maintained or improved cortical and trabecular bone mass, without altering the linear relationship between bone mass and bone strength. J Bone Miner Res 2008, 23(Suppl. 1):S22.
348. Mori H., Tanaka M., Kayasuga R., Masuda T., Ochi Y., Yamada H., et al. Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys. Bone 2008, 43:840-848.
349. Allen M.R., Reinwald S., Burr D.B. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment. Calcif Tissue Int 2008, 82:354-360.
350. Allen M.R., Burr D.B. Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs. Osteoporos Int 2008, 19:95-99.
351. Burr D.B., Diab T., Koivunemi A., Koivunemi M., Allen M.R. Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk. J Orthop Res 2009, 27:1288-1292.
352. Diab T., Allen M.R., Hogan H.A., Burr D.B. Alendronate treatment significantly suppresses bone turnover in the femoral neck without compromising the material properties. Trans Orthop Res Soc 2009, 34:111.
353. Masarachia P.J., Pennypacker B.L., Pickarski M., Scott K.R., Wesolowski G.A., Smith S.Y., et al. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res 2012, 27:509-523.
354. Allen M.R., Hogan H.A., Hobbs W., Koivuniemi A.S., Koivuniemi M.C., Burr D.B. Raloxifene increases intrinsic toughness of trabecular and cortical bone following one-year treatment of beagle dogs. Trans Orthop Res Soc 2007, 32:402.
355. Mizuno A., Amizuka N., Irie K., Murakami A., Fujise N., Kanno T., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998, 247:610-615.
356. Bucay N., Sarosi I., Dunstan C., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268.
357. Weber M., Roschger P., Fratzl-Zelman N., Schöberl T., Rauch F., Glorieux F.H., et al. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta. Bone 2006, 39:616-622.
358. Ominsky M.S., Stolina M., Li X., Corbin T.J., Asuncion F.J., Barrero M., et al. One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density and strength. J Bone Miner Res 2009, 24:1234-1246.
359. Binkley N., Kimmel D., Bruner J., Haffa A., Davidowitz B., Meng C., et al. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res 1998, 13:1775-1782.
360. Ahlborg H.G., Johnell O., Turner C.H., Rannevik G., Karlsson M.K. Bone loss and bone size after menopause. N Engl J Med 2003, 349:327-334.
361. Szulc P., Seeman E., Duboeuf F., Sornet-Rendu E., Delmas P.D. Bone fragility: failure of periosteal apposition to compensate for increased endocortical resorption in postmenopausal women. J Bone Miner Res 2006, 21:1856-1863.
362. Cheng X.G., Nicholson P., Lowet G., Boonen S., Sun Y., Ruegsegger P., et al. Prevalence of trabecular microcallus formation in the vertebral body and the femoral neck. Calcif Tissue Int 1997, 60:479-484.
363. Gerstenfeld L.C., Sacks D.J., Pelis M., Mason Z.D., Graves D.T., Barrero M., et al. Comparison of the effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 2009, 24:196-208.
364. Lee T.C., Staines A., Taylor D. Bone adaptation to load: microdamage as a stimulus for bone remodeling. J Anat 2002, 201:437-446.
365. Lee T.C., Taylor D. Quantification of ovine bone adaptation to altered load: morphometry, density and surface strain. Eur J Morphol 2003, 41:117-125.
366. Li G.P., Zhang S.D., Chen G., Chen H., Wang A.M. Radiographic and histologic analyses of stress fracture in rabbit tibias. Am J Sports Med 1985, 13:285-294.
367. Waldorff E.I., Christenson K.B., Cooney L.A., Goldstein S.A. Microdamage repair and remodeling requires mechanical loading. J Bone Miner Res 2010, 25:734-745.
368. Markel M.D., Wikenheiser M.A., Chao E. A study of fracture callus material properties: relationship to the torsional strength of bone. J Orthop Res 1990, 8:843-850.
369. Jepsen K.J., Price C., Silkman L.J., Nicholls F.H., Nasser P., Hu B., et al. Genetic variation in the patterns of skeletal progenitor cell differentiation and progression during endochondral bone formation affects the rate of fracture healing. J Bone Miner Res 2008, 23:1204-1216.
370. Kim B.T., Mosekilde L., Duan Y., Zhang X.Z., Tornvig L., Thomsen J.S., et al. The structural and hormonal basis of sex differences in peak appendicular bone strength in rats. J Bone Miner Res 2003, 18:150-155.
371. Ellinger G.M., Duckworth J., Dalgarno A.C., Quenouville M.H. Skeletal changes during pregnancy and lactation in the rat: effect of different levels of dietary calcium. Br J Nutr 1952, 6:235-253.
372. Banks W.J., Epling G.P., Kainer R.A., Davis R.W. Antler growth and osteoporosis. I. Morphological and morphometric changes in the costal compacta during the antler growth cycle. Anat Rec 1968, 162:387-398.
373. Riggs B.L., Melton L.J., Robb R.A., Camp J.J., Atkinson E.J., Peterson J.M., et al. Population-based study of age and sex differences in bone volumetric density, size, geometry and structure at different skeletal sites. J Bone Miner Res 2004, 19:1945-1954.
374. Pietschmann P., Skalicky M., Kneissel M., Rauner M., Hofbauer G., Stupphann D., et al. Bone structure and metabolism in a rodent model of male senile osteoporosis. Exp Gerontol 2007, 42:1099-1108.
375. Karsenty G., Ferron M. The contribution of bone to whole-organism physiology. Nature 2012, 481:314-320.
376. Day J.S., Ding M., Bednarz P., van der Linden J.C., Mashiba T., Hirano T., et al. Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties. J Orthop Res 2004, 22:465-471.
377. Cusick T., Chen C.M., Pennypacker B.L., Pickarski M., Kimmel D.B., Scott B.B., et al. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res 2011, 27:524-537.
378. Dempster D.W., Lambing C.L., Kostenuik P.J., Grauer A. Role of RANK ligand in bone health and osteoporosis: laboratory and clinical experience with denosumab, a targeted RANK ligand inhibitor. Clin Ther 2012, 34:521-536.
379. Augat P., Iida H., Jiang Y., Diao E., Genant H.K. Distal radius fractures: mechanisms of injury and strength prediction by bone mineral assessment. J Orthop Res 1998, 16:629-635.
380. Weinstein R.S. True strength. J Bone Miner Res 2000, 15:621-625.